Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
Status:
Active, not recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
This is a single-agent, open label, one-arm phase 2 pilot study of avelumab in patients with
advanced or metastatic adenocarcinoma of the small intestine.